These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 32926652)

  • 1. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of toxicity probability interval based designs in contrast to the continual reassessment method.
    Horton BJ; Wages NA; Conaway MR
    Stat Med; 2017 Jan; 36(2):291-300. PubMed ID: 27435150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM.
    Koopmeiners JS; Wey A
    J Biopharm Stat; 2017; 27(6):1028-1042. PubMed ID: 28340333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to design a dose-finding study using the continual reassessment method.
    Wheeler GM; Mander AP; Bedding A; Brock K; Cornelius V; Grieve AP; Jaki T; Love SB; Odondi L; Weir CJ; Yap C; Bond SJ
    BMC Med Res Methodol; 2019 Jan; 19(1):18. PubMed ID: 30658575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of two-stage continual reassessment method relative to an optimal benchmark.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2013; 10(6):862-75. PubMed ID: 24085776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of irrational dose assignment definitions using the continual reassessment method.
    Wages NA; Bagley E
    Clin Trials; 2019 Dec; 16(6):665-672. PubMed ID: 31547691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.
    James GD; Symeonides S; Marshall J; Young J; Clack G
    BMC Cancer; 2021 Jan; 21(1):7. PubMed ID: 33402104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of phase I cancer clinical trial designs.
    Ahn C
    Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity equivalence range design (TEQR): a practical Phase I design.
    Blanchard MS; Longmate JA
    Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information.
    Yang C; Li Y
    Stat Med; 2024 Feb; 43(4):689-705. PubMed ID: 38110304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shift models for dose-finding in partially ordered groups.
    Horton BJ; Wages NA; Conaway MR
    Clin Trials; 2019 Feb; 16(1):32-40. PubMed ID: 30309262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative review of novel model-assisted designs for phase I clinical trials.
    Zhou H; Murray TA; Pan H; Yuan Y
    Stat Med; 2018 Jun; 37(14):2208-2222. PubMed ID: 29682777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incorporating lower grade toxicity information into dose finding designs.
    Iasonos A; Zohar S; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):370-9. PubMed ID: 21835856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel model of the continual reassessment method in Phase I trial.
    Zhang W; Lei W; Zhu X
    Sci Rep; 2023 Mar; 13(1):5047. PubMed ID: 36977709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.